Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2007

View Archived Issues

New pharmacokinetic data on iloperidone available

Respiratory tract-delivered vaccine confers protection against Ebola virus infection in monkeys

Takeda terminates development of fixed dose Actos + TAK-536 product

AtheroGenics to focus on diabetes for AGI-1067

FDA outlines data requirements for Provenge BLA approval

Treatment completed in prophylactic phase III trial of C1-INH for HAE

Venticute awarded fast track designation

Positive topline phase Ib findings for bavituximab in advanced cancers

Amgen to acquire Ilypsa

BNC-105 shows preclinical efficacy in prostate tumors

MF-101 reduces frequency and severity of postmenopausal hot flashes

Coronado licenses rights from Burnham to develop and commercialize Apogossypol

NIAID grant supports work on fungal antigens in chronic sinusitis

R&D highlights from BIO 2007 in Boston: Zealand Pharma

R&D highlights from BIO 2007 in Boston: BioInvent International

New vascular-targeting agent moves forward to phase II trials based on positive phase I findings

Encouraging findings emerge from first-in-man trial of peptibody AMG-386

First-in-human study of a potent pan-HER tyrosine kinase inhibitor from Pfizer

Positive results for DNA vaccine adjuvant Vaxfectin in nonhuman primates

Phase I study suggests promise for orally active VEGFR/FGFR tyrosine kinase inhibitor

CX-3543, Cylene's lead rDNA biogenesis inhibitor, discussed at ASCO

Audit to be performed on phase III trial results of PreHistin

BAY-73-4506, a multikinase inhibitor, active and well tolerated in advanced cancer

Valeant's retigabine moves towards phase II study in PHN

Recent sanofi-aventis and Kumamoto University patents impart new agents for autoimmune diseases

Priority review for Abilify in pediatric schizophrenia

Biovest to seek conditional approval of BiovaxID

Novel diagnostic agents reported in recent GE Healthcare patent

Divigel approved to treat menopausal hot flashes

Recent Helperby and 3M patents disclose new antiinfective agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...